FOLD at a glance
AMICUS THERAPEUTICS, INC. (FOLD, SEC CIK 1178879) filed its latest 10-K annual report on February 20, 2026, a 10-Q quarterly report on November 4, 2025, an 8-K current report on April 27, 2026 and Form 4 insider filings as recently as April 27, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), AMICUS THERAPEUTICS, INC. (FOLD) reported revenue of $634.2 million (up 20.0% from FY2024) and a net loss of $27.1 million. Diluted EPS was -$0.09.
- As of March 31, 2026, 33 institutional investment managers tracked by SignalX reported holding AMICUS THERAPEUTICS, INC. (FOLD) shares worth $1.9 billion in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $634.2M
- +20.0% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 33 funds
- $1.9B · +6 vs prior quarter
- Latest 8-K
- Apr 27, 2026
- Item 1.02 · Item 3.01 · Item 5.02 · Item 5.03
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: Global biotechnology company focused on developing transformative rare disease medicines including Fabry and Pompe disease therapies
- New emphasis: Licensed exclusive U.S. commercialization rights to Phase 3 FSGS drug candidate DMX-200 in April 2025
- Strategic shift: Definitive merger agreement with BioMarin announced December 2025, $14.50/share cash, expected Q2 2026 close, going private
- Quantitative highlight: 2025 revenue increased to $521.7M for Galafold (+$63.6M YoY) and $112.5M for Pombiliti+Opfolda (+$42.3M YoY)
- Noteworthy fact: Patent litigation resolved with generic challengers Teva, Aurobindo, Lupin, with licensing agreements allowing generics from January 30, 2037
Risk Factors
- Regulatory risk: Pending merger requires Hart-Scott-Rodino Act antitrust approval and clearance from EU and Japanese authorities, risking delays or termination
- Geopolitical risk: Transaction contingent on foreign direct investment approvals in European and Japanese markets, exposing reliance on international regulatory outcomes
- Operational risk: Business restricted under merger agreement, limiting indebtedness, asset transactions, share issuance, potentially stifling strategic opportunities
- Competitive risk: Market erosion threat from competitors’ oral, enzyme replacement, and gene therapies against Galafold® and Pombiliti® + Opfolda®
- Financial risk: $175 million termination fee payable to BioMarin if merger agreement is terminated under specified circumstances, affecting liquidity and operations
Management Discussion & Analysis
- Revenue $634.2M, up $105.9M YoY from $528.3M driven by Galafold and Pombiliti+Opfolda growth plus $13.5M currency impact
- Gross profit $561.3M vs $475.4M; cost of goods sold $72.9M vs $52.9M; operating loss narrowed with net loss $27.1M vs $56.1M
- Best segment: Pombiliti+Opfolda third-party R&D expenses $48.6M up $3.3M; worst: SG&A expenses $383.5M up $60.1M due to litigation and merger costs
- Operating cash flow positive $33.1M vs negative $33.9M; investing cash used $46.4M mostly in marketable securities and capex $3.3M; no share issuances under ATM in 2025
- Management highlights Merger Agreement with BioMarin, expects ongoing R&D expenses, and notes risks from clinical trial outcomes, regulatory environment, and market acceptance
AI summary of the FOLD 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2025
Risk Factors
- No new or changed risk factors disclosed since 2024 10-K
- Carried-forward regulatory risk: reliance on FDA approvals for product pipeline advancement
- Operational risk: dependence on third-party manufacturing affecting supply chain continuity
- Market risk: competition from alternative therapies potentially impacting market share
- Financial risk: limited liquidity with cash runway through mid-2025 requiring additional funding
AI summary of the FOLD 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 1.02: Termination of a Material Definitive Agreement
- April 27, 2026 repayment and termination of Amicus Credit Agreement obligations in connection with the Merger
- All outstanding indebtedness, amounts payable and lender commitments fully extinguished
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule
- Merger consummation transferred control of Amicus Therapeutics to Parent
- Amicus became a wholly owned subsidiary of Parent
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Merger closed; all nine pre-merger directors resigned and left board committees
- Resignations unrelated to disagreements, reducing governance-transition concerns
Item 5.03: Amendments to Articles of Incorporation or Bylaws
- Certificate of incorporation amended and restated at merger closing under the Merger Agreement
- Bylaws amended and restated to conform to Merger Sub’s governance documents
Item 8.01: Other Events
- French FDI clearance received April 23, 2026, satisfying the merger’s final regulatory condition
- BioMarin’s acquisition of Amicus expected to close April 27, 2026
Item 5.07: Submission of Matters to a Vote of Security Holders
- Stockholder approval secured: 234.6M shares (99.9% of votes cast) approved BioMarin acquisition of Amicus, clearing key merger condition
- FTC early termination granted Feb 11, 2026: U.S. antitrust clearance already obtained
AI summaries of FOLD 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for FOLD
Don't miss the next FOLD filing
- Alerts as it files. A push when FOLD files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut FOLD, by share count.
- Ask anything. An AI agent that reads every FOLD filing and answers with sources.
FOLD alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| WHITMAN BURKE W | D | Apr 27, 2026 | 25,964 | - |
| WHITMAN BURKE W | D | Apr 27, 2026 | 18,574 | - |
| Kelly Michael Aaron | D | Apr 27, 2026 | 72,468 | $14.50 |
| Kelly Michael Aaron | D | Apr 27, 2026 | 36,111 | - |
| Kelly Michael Aaron | D | Apr 27, 2026 | 45,423 | - |
| Kelly Michael Aaron | D | Apr 27, 2026 | 30,474 | - |
| Kelly Michael Aaron | D | Apr 27, 2026 | 42,467 | - |
| Kelly Michael Aaron | D | Apr 27, 2026 | 74,872 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $528.3M | $634.2M |
| Gross Profit | - | $475.4M | $561.3M |
| Operating Income | - | $24.9M | $32.8M |
| Net Income | - | -$56.1M | -$27.1M |
| Gross Margin | - | 90.0% | 88.5% |
| Op. Margin | - | 4.7% | 5.2% |
| Net Margin | - | -10.6% | -4.3% |
| Balance Sheet | |||
| Total Assets | $777.9M | $785.0M | $949.9M |
| Equity | $160.2M | $194.0M | $274.2M |
| ROE | - | -28.9% | -9.9% |
| Per Share | |||
| EPS | - | $-0.18 | $-0.09 |
| Cash Flow | |||
| Operating CF | - | -$33.9M | $33.1M |
| CapEx | - | $3.6M | $3.3M |
Source: XBRL data in AMICUS THERAPEUTICS, INC. (FOLD)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q1 2026Aggregate FOLD share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q1 2026 | 33 | $1.92B |
| Q4 2025 | 27 | $1.77B |
| Q3 2025 | 30 | $969.3M |
| Q2 2025 | 28 | $681.4M |
| Q1 2025 | 26 | $666.4M |
| Q4 2024 | 22 | $598.1M |
| Q3 2024 | 19 | $291.7M |
- Goldman Sachs Group+5.41M (+88%)
- Millennium Management+4.86M (+160%)
- JPMorgan Chase & Co+3.03M (+82%)
- Citigroup+2.38M (+129%)
- FMR LLC (Fidelity)+1.58M (+883%)
- Citadel Advisors LLC−5.01M (-98%)
- Blackstone Group−2.40M (-93%)
- State Street Corp−1.94M (-13%)
- D.E. Shaw & Co−1.06M (-68%)
- Invesco Ltd−746.5K (-59%)
- Vanguard Capital Management LLC+14.02M
- Vanguard Portfolio Management LLC+13.97M
- Franklin Resources+129.3K
- Allstate+45.2K
- Paulson & Co+32.4K
- Vanguard Group Inc−29.70M
- Bridgewater Associates LP−32.3K
Source: 13F-HR filings on SEC EDGAR (aggregated from 185 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
FOLD filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| SC 13G | May 14, 2026 | - | - | |
| SC 13G | May 11, 2026 | - | - | |
| SC 13G | May 7, 2026 | - | - | |
| SC 13G | May 1, 2026 | - | - | |
| SC 13G | Apr 29, 2026 | - | - | |
| 4 | Apr 27, 2026 | - | - | - |
| 4 | Apr 27, 2026 | - | - | - |
| 8-K | Apr 27, 2026 | - | Analysis | - |
| 4 | Apr 27, 2026 | - | - | - |
| 4 | Apr 27, 2026 | - | - | - |
| 4 | Apr 27, 2026 | - | - | - |
| 4 | Apr 27, 2026 | - | - | - |
| 4 | Apr 27, 2026 | - | - | - |
| 4 | Apr 27, 2026 | - | - | - |
| 4 | Apr 27, 2026 | - | - | - |
| 4 | Apr 27, 2026 | - | - | - |
| 4 | Apr 27, 2026 | - | - | - |
| 4 | Apr 27, 2026 | - | - | - |
| 4 | Apr 27, 2026 | - | - | - |
| 4 | Apr 27, 2026 | - | - | - |
| 8-K | Apr 23, 2026 | - | Analysis | - |
| 8-K | Mar 3, 2026 | - | Analysis | - |
| 10-K | Feb 20, 2026 | Dec 31, 2025 | Analysis | |
| 8-K | Feb 20, 2026 | - | - | |
| 8-K | Jan 26, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
FOLD SEC filings: frequently asked questions
Which institutions hold FOLD stock?
As of March 31, 2026, the largest AMICUS THERAPEUTICS, INC. (FOLD) holders among the 13F filers tracked by SignalX were BlackRock ($489.9 million), Vanguard Capital Management LLC ($202.8 million), Vanguard Portfolio Management LLC ($202.1 million), State Street Corp ($186.4 million), Goldman Sachs Group ($167.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was FOLD's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), AMICUS THERAPEUTICS, INC. (FOLD) reported revenue of $634.2 million (up 20.0% from FY2024) and a net loss of $27.1 million. Diluted EPS was -$0.09. The figures come from the XBRL data in the 10-K.
What are the main risks in FOLD's latest 10-K?
In the 10-K filed February 20, 2026, AMICUS THERAPEUTICS, INC. (FOLD) flagged: Regulatory risk: Pending merger requires Hart-Scott-Rodino Act antitrust approval and clearance from EU and Japanese authorities, risking delays or termination. Geopolitical risk: Transaction contingent on foreign direct investment approvals in European and Japanese markets, exposing reliance on international regulatory outcomes. (AI summary of the Risk Factors section.)
What did FOLD report in its latest 8-K?
AMICUS THERAPEUTICS, INC. (FOLD) filed an 8-K on April 27, 2026 reporting Item 1.02 (Termination of a Material Definitive Agreement), Item 3.01 (Notice of Delisting or Failure to Satisfy a Continued Listing Rule), Item 5.02 (Departure/Appointment of Directors or Principal Officers) and Item 5.03 (Amendments to Articles of Incorporation or Bylaws). April 27, 2026 repayment and termination of Amicus Credit Agreement obligations in connection with the Merger.
What are the latest FOLD SEC filings?
AMICUS THERAPEUTICS, INC. (FOLD) filed its latest 10-K annual report on February 20, 2026, a 10-Q quarterly report on November 4, 2025, an 8-K current report on April 27, 2026 and a Form 4 insider filing on April 27, 2026.
What is FOLD's SEC CIK number?
AMICUS THERAPEUTICS, INC. (FOLD)'s SEC Central Index Key (CIK) is 1178879. EDGAR lists every FOLD filing under that number.
Ask anything about FOLD
The research agent reads FOLD's filings, financials, insider trades and 13F holders, then answers with sources.